Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Inhibitor clinical burden of disease: a comparative analysis of the CHESS data

Fig. 2

HRU frequency over 12 months for PS-matched patients with and without inhibitors in CHESS studya. a‘N’ pertains to number of patients in each cohort after PS-matching. Patients with current inhibitors were matched to patients who had never developed an inhibitor based on demographics (age, BMI, race) and comorbidity status using propensity scores stratified by hemophilia type. Matching was performed using a preset caliper size of 0.035 to maintain the maximum sample size using the smallest caliper width. bP-values were derived from a paired t-test or Wilcoxon signed rank test for continuous post-match variables; p < .05 indicates statistical significance. Abbreviations: BMI, body mass index; CHESS, Cost of Haemophilia across Europe – a Socioeconomic Survey; HRU, health resource utilization; PS, propensity score; SD, standard deviation

Back to article page